BBV87 Chikungunya Vaccine Description
Bharat Biotech BBV87 vaccine candidate is an inactivated whole virion vaccine based on a strain derived from an East, Central, South African (ECSA) genotype.
BBIL’s BBV87 vaccine has completed standard pre-clinical studies, and an optimum immune response was elicited by the adjuvanted vaccine in phase 1 clinical trials in India.
Chikungunya is an emerging arthritogenic arboviral illness caused by the chikungunya virus (CHIKV), a member of the genus Alphavirus in the Togaviridae family.
The pathologic mechanism of this virus leads to acute infection of several weeks, which can persist for months with an incubation period of 2–12 days. The hallmark characteristics of CHIKV infection are saddle-back fever, polyarthralgia (mainly in small joints – ankles, toes, wrists, and phalanges), and a petechial or maculopapular rash (mainly on the face, limbs, and trunk).
CHIKV affects all age groups with dengue-like symptoms characterized by nausea, fever, chills/rigors, headache, polyarthralagia, myalgia, photophobia, and skin rash.
Bharat Biotech creates innovative vaccines and bio-therapeutics trusted by physicians around the world. BBIL's manufacturing facilities are approved by USFDA, KFDA, and WHO.
BBV87 Chikungunya Vaccine Indication
Inactivated virions technology has a safety profile which potentially makes this vaccine accessible to special populations, such as the immunocompromised and pregnant women, that some other technologies cannot reach.
Chikungunya virus was first identified in Tanzania in 1952, with sporadic outbreaks of the disease reported subsequently across Africa and Asia. In 2004, the disease began to spread quickly, causing large-scale outbreaks around the world. Since the re-emergence of the virus, the total number of cases has been estimated at over 3.4 million in 43 countries.
Explosive outbreaks during the last decade worldwide have prompted the National Institute of Allergy and Infectious Diseases (NIAID) to add CHIKV in the category C priority pathogen biodefense list.
BBV87 Chikungunya Vaccine Dosage
A 2-dose live-inactivated vaccine (BBV87) against Chikungunyais being tested.
BBV87 Chikungunya Vaccine News
June 3, 2020 - The Coalition for Epidemic Preparedness Innovations (CEPI) announced a new partnering agreement to advance the development of a Chikungunya vaccine. The CEPI will provide the consortium with up to US $14.1 million for vaccine manufacturing and clinical development of a 2-dose live-inactivated vaccine (BBV87) against Chikungunya.
June 2, 2020 - Oslo, Norway; Seoul, South Korea; Telangana, India—CEPI, in collaboration with Ind-CEPI, has announced a new partnering agreement with a consortium comprising Bharat Biotech (BBIL) and the International Vaccine Institute (IVI) to advance the development of a Chikungunya vaccine.
BBV87 Chikungunya Vaccine Clinical Trial
The BBV87 vaccine candidate has completed standard pre-clinical studies, and an optimum immune response was elicited by the adjuvanted vaccine in phase 1 clinical trials in India.
